Search Results 231-240 of 16926 for what is vedolizumab
A Study of the Effectiveness of Methotrexate as Initial Treatment and Maintenance of a Steroid Free Remission in Ulcerative Colitis · More about research at Mayo ...
For induction: vedolizumab 300 mg. For maintenance: vedolizumab 300 mg every 4 to 8 weeks. Anti-IL-12/23: at least 16 weeks treatment of the approved dose ...
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's ...
William Faubion Jr., a Mayo Clinic gastroenterologist, says inflammatory bowel disease is an umbrella term that covers Crohn's disease and ulcerative colitis, ...
Open Label Study to Evaluate Long Term Efficacy, Safety and Tolerability of Repeated Dosing in Subjects with Crohn's Disease and Who Participated and ...
A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC) · More about research at Mayo Clinic · Mayo ...
Colonoscopy, Upper endoscopy, Ulcerative colitis, Inflammatory bowel disease, Crohn's disease ... A Book: Mayo Clinic on Crohn's Disease and Ulcerative Colitis ...
This medicine is also used to treat moderate to severe active Crohn's disease and ulcerative colitis. This medicine is available only with your doctor's ...
The purpose of this study is to evaluate the safety, tolerability and microbiome dynamics of SER-287 in subjects with mild-to-moderate ulcerative colitis.
... ulcerative colitis. Hydrocortisone is a corticosteroid (cortisone-like medicine or steroid). It works on the immune system to help relieve swelling, redness ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
The deadline to have twice the impact to advance healthcare research is May 15.